Qiagen N.V. (QGEN) Given Consensus Recommendation of “Hold” by Analysts
Qiagen N.V. (NASDAQ:QGEN) has been assigned an average recommendation of “Hold” from the fifteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $33.36.
QGEN has been the topic of a number of recent analyst reports. TheStreet raised shares of Qiagen from a “c+” rating to a “b+” rating in a research note on Tuesday, November 7th. Deutsche Bank AG reaffirmed a “buy” rating on shares of Qiagen in a research note on Monday, July 31st. Zacks Investment Research raised shares of Qiagen from a “hold” rating to a “buy” rating and set a $39.00 price target on the stock in a research note on Tuesday, October 10th. Commerzbank Ag reaffirmed a “buy” rating on shares of Qiagen in a research note on Tuesday, November 7th. Finally, Cowen Inc reaffirmed a “hold” rating and set a $33.00 price target on shares of Qiagen in a research note on Monday, August 14th.
Qiagen (QGEN) opened at $32.20 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 4.78 and a current ratio of 5.33. The firm has a market cap of $7,330.65, a P/E ratio of 26.18, a price-to-earnings-growth ratio of 1.97 and a beta of 1.13. Qiagen has a one year low of $27.51 and a one year high of $36.34.
Qiagen (NASDAQ:QGEN) last posted its quarterly earnings results on Monday, November 6th. The company reported $0.32 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.32. The company had revenue of $364.00 million for the quarter, compared to the consensus estimate of $363.42 million. Qiagen had a net margin of 6.40% and a return on equity of 11.36%. Qiagen’s revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.29 earnings per share. equities analysts expect that Qiagen will post 1.25 EPS for the current year.
Several institutional investors have recently added to or reduced their stakes in QGEN. Teachers Advisors LLC increased its position in shares of Qiagen by 7.5% in the first quarter. Teachers Advisors LLC now owns 256,353 shares of the company’s stock worth $7,427,000 after acquiring an additional 17,892 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Qiagen by 0.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 73,215 shares of the company’s stock valued at $2,121,000 after purchasing an additional 306 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in Qiagen by 9.8% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 181,545 shares of the company’s stock valued at $5,260,000 after purchasing an additional 16,225 shares in the last quarter. Aperio Group LLC grew its holdings in Qiagen by 2.5% during the 2nd quarter. Aperio Group LLC now owns 207,471 shares of the company’s stock valued at $6,956,000 after purchasing an additional 5,132 shares in the last quarter. Finally, Quantitative Systematic Strategies LLC acquired a new stake in Qiagen during the 2nd quarter valued at $211,000. 59.96% of the stock is owned by institutional investors.
WARNING: “Qiagen N.V. (QGEN) Given Consensus Recommendation of “Hold” by Analysts” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/qiagen-n-v-qgen-given-consensus-recommendation-of-hold-by-analysts/1727206.html.
Qiagen Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.